Ajai Chari

2 weeks ago | ajmc.com | Kyle Munz |Ajai Chari

The future of multiple myeloma treatment is bright, but it hinges on overcoming barriers to access and affordability, argued Ajai Chari, MD, University of California San Francisco, in an interview with The American Journal of Managed Care®. As he previously discussed, chimeric antigen receptor (CAR) T-cell and bispecific therapies have fundamentally altered patient outcomes and quality of life for patients with multiple myeloma (MM).

4 weeks ago | ajmc.com | Kyle Munz |Ajai Chari

Previously, Ajai Chari, MD, University of California San Francisco (UCSF), spoke to the operational challenges of integrating chimeric antigen receptor T-cell (CAR T) and bispecific therapies into clinical practice. Notably, he emphasized the need to educate providers to manage potential adverse events, such as cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).

1 month ago | ajmc.com | Kyle Munz |Ajai Chari

In his previous interview, Ajai Chari, MD, University of California San Francisco, discussed the primary operational challenges health care systems face when they aim to implement chimeric antigen receptor (CAR) T-cell therapies into their practice. As CAR T-cell therapy has proved a valuable treatment option for patients with multiple myeloma, so too has the advent of bispecific therapies.

1 month ago | ajmc.com | Kyle Munz |Ajai Chari

The advent of chimeric antigen receptor (CAR) T-cell therapies has brought numerous advantages to the multiple myeloma treatment landscape; however, implementing these therapies into clinical practice comes with its own challenges. In this interview with The American Journal of Managed Care®, Ajai Chari, MD, University of California San Francisco, points specifically to operational delays that extend “brain-to-vein” time and hamper efforts to provide these therapies on the community level.

Nov 26, 2024 | cancernetwork.com | Morie A Gertz |Ajai Chari

November 26, 2024By Panelists discuss how the CEPHEUS trial’s demonstration of improved progression-free survival with daratumumab-VRd versus VRd alone in transplant not-preferred NDMM provides compelling evidence for quadruplet therapy in this setting, though considerations of cost, toxicity management, and patient selection remain important factors in implementation. Video content above is prompted by the following:What are your impressions of the CEPHEUS data that was recently presented?